New COVID-19 Vaccine Codes: May Update

The Current Procedural Terminology (CPT®) Editorial Panel (the Panel) has approved a new vaccine product code (91311) and its associated vaccine administration codes (0111A, 0112A) for the new Moderna vaccine product to address severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) in pediatric patients aged 6 months through 5 years. These codes will become effective upon receiving the emergency use authorization (EUA) from the Food and Drug Administration (FDA).

In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated immunization administration codes, the American Medical Association (AMA) established a website (https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes) that features timely updates of the Panel’s actions. The last COVID-19 update was in the CPT® Assistant Special Edition: April Update (2022) in which the Sanofi Pasteur vaccine product (91310) and vaccine administration (0104A) codes for adult patients aged 18 years and older were discussed.

This issue of CPT® Assistant Special Edition introduces and provides guidance on the appropriate use of the new Moderna vaccine product code (91311) and its associated vaccine administration codes (0111A, 0112A) for pediatric patients aged 6 months through 5 years.
Immunization Administration for Vaccines/Toxoids

#✓● 0111A  Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose

#✓● 0112A  second dose

►(Report 0111A, 0112A for the administration of vaccine 91311)
►(Do not report 0111A, 0112A in conjunction with 91301, 91306, 91309)

Vaccines, Toxoids

#✓● 91311  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 25 mcg/0.25 mL dosage, for intramuscular use

►(Report 91311 with administration codes 0111A, 0112A)
►(Do not report 91311 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0094A)

Code 91311 describes Moderna’s new vaccine product for pediatric patients aged 6 months through 5 years. This vaccine uses a 25 mcg/0.25 mL dosage concentration. Vaccine administration code 0111A should be reported for the administration of the first dose of the primary series and with code 0112A for the second dose of the primary series.

As with previous COVID-19 vaccine administration codes, counseling is included as part of the administration visit and should not be reported separately. The physician or other qualified health care professional (QHP) should exercise clinical judgment to determine whether the administration of the vaccine product is appropriate for a given patient. More information on current guidance from the Centers for Disease Control and Prevention regarding which patients should receive a COVID-19 vaccine booster dose is available at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html.

Note that vaccine administration codes 0111A and 0112A are only intended to be reported with vaccine product code 91311. Parenthetical notes have been added following the administration and product codes to clarify the appropriate use of these new codes.
To accommodate the new coding structure, Appendix Q was added to the CPT code set. Appendix Q details the vaccine codes, their associated vaccine administration code(s), the vaccine manufacturers and names, the National Drug Code (NDC) labeler product ID, and dosing intervals. As of this publication, Appendix Q has been reformatted to also show appropriate age bands for each vaccine product and the associated vaccine administration codes to assist in providing clarity for the user. The new Moderna vaccine product (91311) and vaccine administration codes (0111A, 0112A) for pediatric patients aged 6 months through 5 years been added to Appendix Q.


The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

Clinical Example (91311)
A parent or guardian of a 1-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (91311)
The physician or other qualified healthcare professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Clinical Example (011AA)
A parent or guardian of a 1-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0111A)
The physician or other QHP reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the first dose of
the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient’s immunization record (and registry when applicable) to reflect the vaccine administered.

**Clinical Example (0112A)**

A parent or guardian of a 1-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

**Description of Procedure (0112A)**

The physician or other QHP reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the second dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient’s immunization record (and registry when applicable) to reflect the vaccine administered.